ClinicalTrials.gov
ClinicalTrials.gov Menu

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03624959
Recruitment Status : Recruiting
First Posted : August 10, 2018
Last Update Posted : December 14, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:

The purpose of this study is to evaluate the effect of the following index inhibitors or inducers of CYP2C8 and/or CYP3A on the single-dose pharmacokinetics (PK) of ozanimod and its major active metabolite, CC112273, in healthy adult subjects: gemfibrozil (strong inhibitor of CYP2C8), rifampin (moderate inducer of CYP2C8 and strong inducer of CYP3A), and itraconazole (strong inhibitor of CYP3A).

Study Design

This is a Phase 1, randomized, parallel-group, open-label study with two parts, 1 and 2. Forty subjects will be enrolled in Part 1 and will be randomized into 1 of the 2 treatment groups, with 20 subjects in each treatment group. Sixty subjects will be enrolled in Part 2 and will be randomized into 1 of the 3 treatment groups, with 20 subjects in each treatment group. . Study parts and treatment groups are as follow:

Part 1:

  • Treatment Group A (reference): A single dose of ozanimod.
  • Treatment Group B (test): Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod will be coadministered with the morning dose of gemfibrozil.

Part 2:

  • Treatment Group C (reference): A single dose of ozanimod.
  • Treatment Group D (test): Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod will be coadministered with itraconazole.
  • Treatment Group E (test): Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod will be coadministered with rifampin.

Study Population Subjects will be healthy men and non-pregnant, non-lactating women, ages 18 to 55 years, inclusive, with a body weight of at least 110 pounds (50 kg); body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive.

Length of Study The study duration ranges from 43 days to 50 days.


Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: Ozanimod Drug: Gemfibrozil Drug: Itraconazole Drug: Rifampin Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effect of the Modulators of the Cytochrome P450 (CYP) 2C8 and/or 3A on the Single-Dose Pharmacokinetics of Ozanimod and CC112273 in Healthy Adult Subjects
Actual Study Start Date : June 20, 2018
Estimated Primary Completion Date : January 24, 2019
Estimated Study Completion Date : April 15, 2019

Arm Intervention/treatment
Experimental: Treatment Group A - Ozanimod 0.46mg
A single dose of ozanimod 0.46 mg on Day 1
Drug: Ozanimod
ozanimod

Experimental: Treatment Group B - Ozanimod plus Gemfibrozil
Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
Drug: Ozanimod
ozanimod

Drug: Gemfibrozil
Gemfibrozil

Experimental: Treatment Group C - Ozanimod 0.92mg
A single dose of ozanimod 0.92 mg on Day 1.
Drug: Ozanimod
ozanimod

Experimental: Treatment Group D - Ozanimod plus Itraconazole
Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
Drug: Ozanimod
ozanimod

Drug: Itraconazole
Itraconazole

Experimental: Treatment Group E - Ozanimod plus Rifampin
Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
Drug: Ozanimod
ozanimod

Drug: Rifampin
Rifampin




Primary Outcome Measures :
  1. Pharmacokinetics- Cmax [ Time Frame: Up to 14 days after ozanimod dosing ]
    Maximum observed plasma concentration

  2. Pharmacokinetics- AUC∞ [ Time Frame: Up to 14 days after ozanimod dosing ]
    Area under the concentration-time curve from time 0 to infinity

  3. Pharmacokinetics- AUC0-14d [ Time Frame: Up to 14 days after ozanimod dosing ]
    Area under the concentration-time curve from time 0 to 14 days post dose


Secondary Outcome Measures :
  1. Adverse Events (AEs) [ Time Frame: From enrollment until at least 75 days after ozanimod dosing ]
    The incidence, severity, and relationship of TEAEs

  2. Pharmacokinetics- Tmax [ Time Frame: Up to 14 days after ozanimod dosing ]
    Time to Cmax

  3. Pharmacokinetics- CL/F [ Time Frame: Up to 14 days after ozanimod dosing ]
    Apparent oral clearance

  4. Pharmacokinetics- Vz/F [ Time Frame: Up to 14 days after ozanimod dosing ]
    Apparent volume of distribution during terminal phase after oral administration

  5. Pharmacokinetics- λz [ Time Frame: Up to 14 days after ozanimod dosing ]
    Terminal elimination rate constant

  6. Pharmacokinetics- t1/2 [ Time Frame: Up to 14 days after ozanimod dosing ]
    Terminal elimination half-life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is a man or non-pregnant, non-lactating woman, ages 18 to 55 years, inclusive, at the time of signing of the informed consent form (ICF).
  2. Female subjects must meet at least 1 of the following criteria:

    • Negative serum pregnancy test at Screening and Day -1 (women of child-bearing potential [WOCBP] only).
    • Postmenopausal (defined as 2 years after the last period and follicle-stimulating hormone [FSH] > 40 IU/L).
    • Received surgical sterilization (eg, bilateral tubal ligation, bilateral oophorectomy, hysterectomy) at least 6 months before Screening with medical records.
  3. Females of child-bearing potential:

    Must agree to practice a highly effective method of contraception throughout the study until completion of the 75-day Safety Follow-up. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly.

    Acceptable methods of birth control in this study are the following:

    • Combined hormonal (oestrogen and progestogen containing) contraception, which may be oral, intravaginal, or transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation, which may be oral, injectable, implantable
    • Placement of an intrauterine device or intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomized partner
    • Sexual abstinence

    Male subjects:

    Must agree to use a latex condom with spermicide during sexual contact with WOCBP while participating in the study and until completion of the 75-day Safety Follow-up.

    All subjects:

    Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

  4. Male subjects must agree to refrain from donating sperm throughout the study and until completion of the 75-day Safety Follow-up.
  5. Subject has a body weight of at least 110 pounds (50 kg); body mass index (BMI) within the range of 18.0 to 30.0 kg/m2, inclusive (Screening and Day -1).
  6. Subject is in good health, as determined by no clinically significant findings from medical or surgical history, 12-lead ECG, physical examination, clinical laboratory tests, and vital signs.
  7. Subject must be able to comprehend and provide written informed consent, and must be able to comply with the requirements of the study, including the study visit schedule and other protocol requirements.

Exclusion Criteria:

  1. Subject with a seated blood pressure outside 90 to 140 mmHg systolic or 50 to 90 mmHg diastolic at Screening or Day -1.
  2. Subject with a seated pulse rate outside 55 to 90 bpm at Screening or Day -1.
  3. Subject has a presence or history of any abnormality or illness that, in the opinion of the investigator, may affect absorption, distribution, metabolism, or elimination of the Investigational product (IP) or would limit the subject's ability to participate in and complete this clinical study.
  4. Subject has a history of alcoholism, drug abuse, or addiction within 24 months prior to Screening.
  5. Subject has a positive serum test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  6. Subject has used any tobacco- or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, electronic cigarettes, vape, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) or marijuana (cigarette, joint, vape, edibles, etc) within 3 months prior to the first dose of IP.
  7. Subject has a positive urine drug test including cotinine at Screening or Day -1.
  8. Subject has a positive alcohol urine or breath test at Screening or Day -1.
  9. Subject has received any investigational drug within 30 days or 5 times the elimination half-life (if known), whichever is longer, prior to the first dose of IP.
  10. Subject has used any systemic over-the-counter medication (excluding acetaminophen up to 1 g/day), dietary or herbal supplement (excluding vitamins/multivitamins) within 7 days prior to the first dose of IP. St. John's wort, naringenin, curcurmin/turmeric, passion flower, and quercetin must be discontinued at least 28 days prior to the first dose of IP.
  11. Subject has used any systemic prescription medication (excluding hormonal contraceptives) within 28 days or 5 times the elimination half-life, whichever is longer, prior to the first dose of IP.
  12. Subject has ingested alcohol within 7 days prior to the first dose of IP.
  13. Subject fails or is unwilling to abstain from strenuous physical activities for at least 24 hours prior to the first dose of IP.
  14. Subject has poor peripheral venous access.
  15. Subject has donated greater than 400 mL of blood within 60 days prior to Day 1.
  16. Subject has a history of any medical condition or medical history that, in the opinion of the investigator, might confound the results of the study or jeopardize the safety or welfare of the subject.
  17. Subject has history of hypersensitivity or allergic reaction to S1P receptor modulators (both Parts 1 and 2), gemfibrozil (Part 1 only), itraconazole or other azole antifungals (Part 2 only), or rifampin (Part 2 only).
  18. Subject has a history of gall bladder disease (Part 2 only).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03624959


Contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
United States, Texas
PPD Phase 1 Clinic Recruiting
Austin, Texas, United States, 78744
Sponsors and Collaborators
Celgene
Investigators
Study Director: Jonathan Tran, Pharm.D Celgene Corporation

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03624959     History of Changes
Other Study ID Numbers: RPC01-1912
U1111-1215-6965 ( Other Identifier: WHO )
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: December 14, 2018
Last Verified: December 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Celgene:
Healthy Volunteer
Cytochrome P450 (CYP)
ozanimod

Additional relevant MeSH terms:
Itraconazole
Hydroxyitraconazole
Rifampin
Gemfibrozil
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Hypolipidemic Agents
Antimetabolites
Lipid Regulating Agents
Cytochrome P-450 CYP2C8 Inhibitors